Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer-Reference-Cited by-同舟云学术

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer

Published:2024-05-04 Issue:9 Volume:29 Page:e1149-e1158
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Boisteau Emeric¹^ORCID,Dahan Laetitia²^ORCID,Williet Nicolas³,Le Malicot Karine⁴^ORCID,Desramé Jérôme⁵,Bouché Olivier⁶,Petorin Caroline⁷,Malka David⁸,Rebischung Christine⁹,Aparicio Thomas¹⁰,Lecaille Cédric¹¹,Rinaldi Yves¹²,Turpin Anthony¹³,Bignon Anne-Laure¹⁴,Bachet Jean-Baptiste¹⁵^ORCID,Lepage Côme¹⁶,Granger Victoire¹⁷,Legoux Jean-Louis¹⁸,Deplanque Gaël¹⁹,Baconnier Mathieu²⁰,Lecomte Thierry²¹,Bonnet Isabelle²²,Seitz Jean-François²,François Eric²³,Lièvre Astrid¹, ,Pigui Anna²⁴,Escande Anne²⁵,Pezet Denis²⁶,Duluc Muriel²⁷,Barriere Nicolas²⁸,Moullet Isabelle²⁹,Audemar Franck³⁰,Bourgeois Vincent³¹,Vimal-Baguet Agnès³²,Norguet Emmanuelle²⁷,Lagasse Jean-Paul³³,Duchmann Jean-Christophe³⁴,Guillet Marielle³⁵,Berdah Stéphane³⁶,Sverdlin Robert³⁷,Taieb Julien³⁸,Corbinais Stéphane³⁹,Lledo Gérard⁴⁰,Bedenne Laurent⁴¹,Hebbar Mohamed⁴²,Bouhier-Leporrier Karine⁴³,Ferte Charles⁴⁴,Staudacher Lionel⁴⁵,Evesque Ludovic⁴⁶,Remy Stéphane⁴⁷,Charlois Thierry⁴⁸,Lombard-Bohas Catherine⁴⁹,Zaanan Aziz³⁸,Cornila Corina⁵⁰,Hollebecque Antoine⁵¹,Artru Pascal⁴⁰,Dupont Kazma Laure⁵²,Walter Thomas⁴⁹,Devaure Iris⁵²,Gigout Julie²⁸,Desauw ⁵³,Guilngar Anne⁴⁷,Locher Christophe⁵⁴,Ezenfis Joël⁵⁵,Belletier ⁵⁶,Boige Valérie⁵⁷,Cattan Stéphane⁴²,Coufon Caroline⁵⁸,Sibertin-Blanc Camille²⁷,Villing Anne-Laure⁵⁹,Burtin Pascal⁵⁷,Boulat ⁶⁰,Andrau Pierre⁶¹,Meunier Jérôme⁶²,Foll Le⁶³,Ducreux Michel⁵⁷,Plastaras Laurianne⁶⁴,Breysacher Gilles⁶⁵,Bernard Philippe³⁶,Durand Aurelie⁶⁶,Romano Olivier⁶⁷,Farneti Delphine⁶⁸,Simon Mireille⁶⁹,Talarmin Marie⁷⁰,Dupont Gossart Anne-Claire⁷¹,Le Sourd Samuel⁷²,Hocine Fayçal⁷³,Sefrioui David⁷⁴,Le Roy Florence⁴⁴,Desgrippes Romain⁷⁵,Topolski Amalia⁶⁵,Mary Florence⁷⁶,Michel Pierre⁷⁴,Aparicio Thomas⁷⁶,Cavaglione Gérard⁴⁶,Baba-Hamed Nabil³⁷,Follana Philippe⁴⁶,Cumin Isabelle⁵⁸,Thomas Marques Laurence⁵⁴,Baize Nathalie⁷⁷,Arsenii Nicolae⁷⁸,Ceban Tatiana⁷⁹,Jouve Jean-Louis⁴¹,Molin Yann²⁹,Pracht Marc⁸⁰

Affiliation:

1. Department of Gastroenterology, University Hospital Pontchaillou, Rennes 1 University, INSERM U1242 “Chemistry Oncogenesis Stress Signalling ,” Rennes , France

2. Department of Digestive Oncology, La Timone, AMU , Marseille , France

3. Hepatogastroenterology Department, University Hospital of Saint-Etienne , Saint-Etienne , France

4. Biostatistics Department, Francophone Federation of Digestive Cancerology, EPICAD INSERM LNC-UMR 1231 University of Burgundy and Franche Comté , Dijon , France

5. Jean Mermoz Private Hospital , Lyon , France

6. Department of Digestive Oncology, CHU Reims , Reims , France

7. Department of Digestive Oncology, University Hospital d’Estaing , Clermont-Ferrand , France

8. Department of Hepato-Gastroenterology, Gustave Roussy Cancer Campus , Villejuif , France

9. Savoie Medipole , Challes-Les-Eaux , France

10. Department of Gastroenterology, Saint Louis Hospital, APHP, Université de Paris , Paris , France

11. Oncology Department, Polyclinique Nord , Bordeaux , France

12. Department of Hepato-gastroenterology, European Hospital , Marseille , France

13. Univ. Lille, CNRS UMR9020, Inserm UMR-S 1277, Canther, Cancer Heterogeneity, Plasticity and Resistance to Therapies, CHU Lille, Department of Medical Oncology , Lille , France

14. Department of Digestive Oncology, University Hospital Côte de Nacre , Caen , France

15. Department of Hepato-gastroenterology, Pitié-Salpêtrière Hospital , Paris , France

16. Department of Hepato-gastroenterology, University hospital of Dijon, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté , Dijon , France

17. Department of Hepato-gastroenterology and Digestive Oncology, University Hospital of Grenoble Alpes , Grenoble , France

18. Department of Hepato-gastroenterology and Digestive Oncology, Orléans Regional Hospital , Orléans , France

19. Department of Hepato-Gastroenterology, Saint-Joseph Hospital , Paris , France

20. Department of Hepato-Gastroenterology, Annecy-Genevois Hospital Center , Epagny Metz-Tessy , France

21. Department of Hepato-Gastroenterology and Digestive Oncology, University Hospital of Tours; UMR INSERM 1069 Nutrition, Croissance et Cancer, University of Tours , Tours , France

22. Department of Oncology , Valenciennes , France

23. Antoine Lacassagne Center, Oncology Department , Nice , France

24. Centre Hospitalier de Béziers, service d’ HGE, 2 rue Valentin Hauy, 34525 Béziers

25. Clinique Sainte Anne, département d’hématologie et d’oncologie, 184 route La Wantzenau, 67085 Strasbourg

26. service de chirurgie digestive, 1 place Lucie Aubrac, 63003 Clermond Ferrand

27. CHU La Timone, service d’oncologie digestive, 264 Rue Saint Pierre, 13385 Marseille

28. Hôpital Européen, service d’HGE, 26 boulevard Louvain, 13285 Marseille

29. Clinique de la Sauvegarde, centre de cancérologie médicale et d’hématologie, 480 Avenue Ben Gourion, 69009 Lyon

30. Centre Hospitalier de la Côte Basque, service d’HGE, 13 Av Interne Jacques Loeb, 64109 Bayonne

31. Hôpital Duchenne, service d’oncologie Digestive, Allée Jacques Monod, 62321 Boulogne Sur Mer

32. service d’oncologie digestive, 1 place Lucie Aubrac, 63003 Clermond Ferrand

33. Hôpital de La Source, service d’HGE, 14 Avenue de l’Hôpital, 45067 Orléans

34. Centre Hospitalier de Compiègne, Service d’HGE, 8 Avenue Henri Adnot 60321 Compiègne

35. Hôpital de la Croix Rousse, service d’HGE—CCC, 103 Grande Rue de la Croix Rousse, 69317 Lyon

36. Clinique Sainte Marguerite, service d’oncologie, avenue Alexis Godillot, 83400 Hyères

37. Groupe Hospitalier Saint Joseph, service d’oncologie, 185 rue Raymond Losserand, 75014 Paris

38. Hôpital Européen Georges Pompidou, service d’HGE, 20 rue Leblanc, 75015 Paris

39. Service de Médecine II A, 1 rue de la Marne, 35403 Saint Malo

40. Hôpital Privé Jean Mermoz, Institut de Cancérologie, 55 Avenue Jean Mermoz, 69008 Lyon

41. Centre hospitalier universitaire F. Mitterrand Dijon-Bourgogne, service d’HGE et de cancérologie digestive, 14 Rue Paul Gaffarel, 21000 Dijon

42. Hôpital Claude Huriez, service Maladies Appareil Digestif, 1 place de Verdun 59037 Lille

43. CHU Côte de Nacre, service d’HGE, avenue Côte de Nacre, 14033 Caen

44. Institut Gustave Roussy, département de médecine, 114 rue Edouard Vaillant, 94805 Villejuif

45. Groupe Hospitalier Saint Joseph, service de Pneumologie, 185 rue Raymond Losserand, 75014 Paris

46. Centre Antoine Lacassagne, service d’oncologie, 33 Avenue Valombrose, 06189 Nice

47. Centre d’Oncologie et de radiothérapie du Pays-Basque, service d’oncologie 14 allées Paulmy, 64100 Bayonne

48. Centre Hospitalier Départemental de Vendée, service d’HGE, boulevard Stéphane Moreau, 85925 La Roche sur Yon

49. Hôpital Edouard Herriot, service d’Oncologie, 5 Place Arsonval, 69437 Lyon

50. Hôpital de La Source, service d’oncologie, 14 Avenue de l’Hôpital, 45067 Orléans

51. Institut Gustave Roussy, service d’HGE, 114 rue Edouard Vaillant, 94805 Villejuif

52. Polyclinique Bordeaux Nord, service d’HGE, 15-33 rue Claude Boucher, 33300 Bordeaux

53. Hôpital Claude Huriez, service d’oncologie médicale, 1 place de Verdun 59037 Lille

54. GHI de l’Est Francilien, service de gastroentérologie, 6-8 Rue Saint Fiacre, 77100 Meaux

55. Centre Hospitalier Sud Francilien, service d’Oncologie, 40 av. Serge Dassault, 91106 Corbeil-Essonnes

56. Institut de Cancérologie de Strasbourg Europe, service d’HGE, 17 rue Albert Calmette, 67200 Strasbourg

57. Institut Gustave Roussy, service de Cancérologie Digestive, 114 rue Edouard Vaillant, 94805 Villejuif

58. Hôpital du Scorff -Groupe Hospitalier Bretagne Sud - Lorient, service d’HGE, 5 Avenue de Choiseul, 56322 Lorient

59. Centre Hospitalier d’Auxerre, service d’Oncologie, 2 boulevard de Verdun, 89000 Auxerre

60. Hôpital Henri Duffaut, service Médecine Interne, 305 Rue Raoul Follereau, 84902 Avignon

61. Centre Hospitalier de Bigorre, service d’HE, Bd Mal de Lattre de Tassigny, 65013 Tarbes

62. Hôpital de La Source, Service d’Onco/Hématologie, 14 Avenue de l’Hôpital, 45067 Orléans

63. Ch Marne La ValléE-Jossigny, Service D’Oncologie MéDicale, 2-4 Cours De La Gondoire, 77600 Jossigny

64. HôPitaux Civils De Colmar Service De MéDecine A, 39 Avenue De La Liberté, 68024 Colmar

65. HôPitaux Civils De Colmar, Service De MéDecine A, 39 Avenue De La Liberté, 68024 Colmar

66. GHM Institut Daniel Hollard, service d’oncologie, 8 rue du Dr Calmette, 38028 Grenoble

67. Institut Cancérologie Lille Métropole, 20 avenue de la Reconnaissance, 59657 Villeneuve d’Ascq

68. Hôpital Nord Michallon, oncologie médicale, Bd de la Chantourne, 38700 La Tronche

69. Centre Hospitalier de Pau, service d’HGE, 4 Boulevard de Hauterive, 64046 Pau

70. Centre Eugène Marquis, service d’oncologie, avenue de la Bataille Flandre Dunkerque, 35000 Rennes

71. Centre hospitalier universitaire Jean-Minjoz, service d’HGE, 3 Boulevard Alexandre Fleming, 25030 Besançon

72. Centre Eugène Marquis, service d’oncologie médicale, avenue de la Bataille Flandre Dunkerque, 35000 Rennes

73. Centre Hospitalier de Beauvais, service d’oncologie, 40 Avenue Léon Blum, 60021 Beauvais

74. CHU Charles Nicolle, service d’HGE, 1 rue de Germont, 76031 Rouen

75. service Hépato-gastro-entérologie, 1 rue de la Marne, 35403 Saint Malo

76. Hôpital Avicenne, service d’HGE, 125 rue de Stalingrad, 93000 Bobigny

77. Centre hospitalier universitaire d’Angers, service d’HGE, 4 rue Larrey, 49933 Angers

78. Centre hospitalier universitaire de Reims, service d’HGE, avenue du Général Koenig, 51100 Reims

79. Centre hospitalier de Dunkerque, service d’oncologie, 130 avenue Louis Herbeaux, 59385 DUNKERQUE

80. Centre Eugène Marquis, service d’oncologie médicale, avenue de la Bataille Flandre Dunkerque, 35000 Rennes)

Abstract

Abstract Introduction Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this strategy. Patients and Methods We focused on patients who received 12 cycles of FOLFIRINOX (arm A, N = 88) or 8 cycles of FOLFIRINOX followed by LV5FU2 maintenance in controlled patients (arm B, N = 91) from the PRODIGE-35 trial. Prognostic factors and predictors of efficiency were identified by using Cox regression. Median progression-free survival (PFS), overall survival (OS), and time to deterioration of quality of life (TTD-QoL) were evaluated. Results Poor independent prognostic factors were primary tumor in place, age <65 years and the presence of liver metastases for PFS, a baseline neutrophil/lymphocyte ratio (NLR) ≥5 and CA19.9 ≥500 UI/L for OS, independent of the treatment arm. Patients with one metastatic site had a longer PFS in arm A, whereas patients with ≥2 metastatic sites had a longer PFS in arm B. We also identified predictors of OS and TTD-QoL in arm B but these differences were not statistically significant. Conclusion Except for patients with one metastatic site who benefited more from 12 cycles of FOLFIRINOX, a maintenance strategy with LV5FU2 should be widely offered to mPC patients whose survival and QoL are preserved after 4 months of FOLFIRINOX. (ClinicalTrials.gov: NCT02352337).

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/oncolo/article-pdf/29/9/e1149/59036766/oyae079.pdf

Reference21 articles.

1. Épidémiologie du cancer du pancréas;Drouillard;Bull Cancer,2018

2. Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database;Maire;Eur J Gastroenterol Hepatol,2017

3. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014

4. More deaths from pancreatic cancer than breast cancer in the EU by 2017;Ferlay;Acta Oncol,2016

5. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011